Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Michael P. Pender(The University of Queensland), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Sweera Rehan(QIMR Berghofer Medical Research Institute), Blake T. Aftab(Unknown), Katherine Matthews, Corey Smith(QIMR Berghofer Medical Research Institute), Kerryn A. Green(The University of Queensland), Peter A. Csurhes(The University of Queensland), Alan Coulthard(Mental Health Research Institute), Zara A. Ioannides(The University of Queensland), Kate Thompson(The University of Queensland), Stefan Blum, Andrew Swayne, Scott R. Burrows(Australian National University), Nanette L. Douglas(The University of Queensland), Michelle A. Neller(QIMR Berghofer Medical Research Institute), Kaye D. Hooper(The University of Queensland), Leone Beagley, Tracey Hopkins(Royal Brisbane and Women's Hospital), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Cited by 20
Related Papers
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
|New England Journal of Medicine|2018|856
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
|The Journal of Experimental Medicine|1992|391
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
|Proceedings of the National Academy of Sciences|1999|332